Publicacions
-
Pascual-Pastó G, Bazan-Peregrino M, Gene-Olaciregui N, Restrepo-Perdomo CA, Mato-Berciano A, Ottaviani D, Weber K, Correa MG, Paco-Mercader S, Vilà-Ubach M, Cuadrado-Vilanova M, Castillo H, Botteri G, García-Gerique L, Moreno-Gilabert H, Gimenez-Alejandre M, Alonso-Lopez P, Farrera-Sal M, Torres-Manjon S, Ramos-Lozano D, Moreno R, Aerts I, Doz F, Cassoux N, Chapeaublanc E, Torrebadell-Burriel M, Roldan-Molina M, König A, Suñol M, Claverol J, Lavarino C, de Torres C, Fu L, Radvanyi F, Munier FL, Català-Mora J, Mora J, Alemany R, Cascallo M, Chantada G and Carcaboso AM.
Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01
Science Translational Medicine . 11(476): 9321. Nº de cites: 100
-
Gaillard S, Malik S, Preston J, Nafria-Escalera B, Dicks P, Touil N, Mardirossian S, Claverol J and Kassai B.
Involving children and young people in clinical research through the forum of a European Young Persons' Advisory Group: needs and challenges.
FUNDAMENTAL & CLINICAL PHARMACOLOGY . 32(4): 357-362. Nº de cites: 44
-
Novák Z, Yáñez A, Kiss I, Kuna P, Tortajada-Girbés M and Valiente R.
Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases.
PEDIATRIC ALLERGY AND IMMUNOLOGY . 27(5): 493-498. Nº de cites: 41
